Assessment of Cirrhotic Liver Enhancement with Multiphasic Computed Tomography Using a Faster Injection Rate,Late Arterial Phase,and Weight-Based Contrast Dosing

Abstract

French

Purpose

This study aimed to update our liver computed tomography (CT) protocol according to published guidelines, and to quantitatively evaluate the effect of these modifications.

Methods

The modified liver CT protocol employed a faster injection rate (5 vs 3 mL/s), later arterial phase (20-second vs 10-second postbolus trigger), and weight-based dosing of iodinated contrast (1.7 mL/kg vs 100 mL fixed dose). Liver and vascular attenuation values were measured on CTs of patients with cirrhosis from January to September 2015 (old protocol, n = 49) and from October to December 2015 (modified protocol, n = 31). CTs were considered adequate if liver enhancement exceeded 50 Hounsfield units (HU) in portal venous phase, or when the unenhanced phase was unavailable, if a minimum iodine concentration of 500 mg I/kg was achieved. Attenuations and iodine concentrations were compared using the t test and the number of suboptimal studies was compared with Fisher's exact test.

Results

CTs acquired with the modified protocol demonstrated higher aortic (P = .001) and portal vein (P < .0001) attenuations in the arterial phase as well as greater hepatic attenuation on all postcontrast phases (P = .0006, .002, and .003 for arterial, venous, and equilibrium phases, respectively). Hepatic enhancement in the portal venous phase (61 ± 15 HU vs 51 ± 16 HU; P = .0282) and iodine concentrations (595 ± 88 mg I/kg vs 456 ± 112 mg I/kg; P < .0001) were improved, and the number of suboptimal studies was reduced from 57% to 23% (P = .01).

Conclusions

A liver CT protocol with later arterial phase, faster injection rate, and weight-based dosing of intravenous contrast significantly improves liver enhancement and iodine concentrations in patients with cirrhosis, resulting in significantly fewer suboptimal studies.

Keywords

Cirrhosis Iodinated contrast media Liver imaging Multidetector computed tomography

Get full access to this article

View all access options for this article.

References

Mittal

El-Serag

H.B.

Epidemiology of hepatocellular carcinoma: consider the population

J Clin Gastroenterol 47 suppl 2013 S2–S6.

Jemal

Bray

Center

M.M.

Ferlay

Ward

Forman

Global cancer statistics

CA Cancer J Clin 2011; 61:69–90.

Bruix

Sherman

American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update

Hepatology 2011; 53:1020–1022.

McEvoy

S.H.

McCarthy

C.J.

Lavelle

L.P.

Hepatocellular carcinoma: illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the Study of Liver Diseases

Radiographics 2013; 33:1653–1668.

Wald

Russo

M.W.

Heimbach

J.K.

Hussain

H.K.

Pomfret

E.A.

Bruix

New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma

Radiology 2013; 266:376–382.

Bae

K.T.

Intravenous contrast medium administration and scan timing at CT: considerations and approaches

Radiology 2010; 256:32–61.

Koiwahara

Tsuda

Matsuda

Different enhancement of the hepatic parenchyma in dynamic CT for patients with normal liver and chronic liver diseases and with the dose of contrast medium based on body surface area

Jpn J Radiol 2015; 33:194–200.

Van Beers

B.E.

Leconte

Materne

Smith

A.M.

Jamart

Horsmans

Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity

AJR Am J Roentgenol 2001; 176:667–673.

Zissen

M.H.

Wang

Z.J.

Yee

Aslam

Monto

Yeh

B.M.

Contrast-enhanced CT quantification of the hepatic fractional extracellular space: correlation with diffuse liver disease severity

AJR Am J Roentgenol 2013; 201:1204–1210.

10.

American College of Radiology. Liver Imaging Reporting and Data System (LI-RADS) version 2014. Available at: http://www.acr.org/Quality-Safety/Resources/LIRADS. Accessed August 17, 2016.

11.

Fleischmann

Kamaya

Optimal vascular and parenchymal contrast enhancement: the current state of the art

Radiol Clin North Am 2009; 47:13–26.

12.

Foley

W.D.

Mallisee

T.A.

Hohenwalter

M.D.

Wilson

C.R.

Quiroz

F.A.

Taylor

A.J.

Multiphase hepatic CT with a multirow detector CT scanner

AJR Am J Roentgenol 2000; 175:679–685.

13.

Fujigai

Kumano

Okada

Optimal dose of contrast medium for depiction of hypervascular HCC on dynamic MDCT

Eur J Radiol 2012; 81:2978–2983.

14.

Heiken

J.P.

Brink

J.A.

McClennan

B.L.

Sagel

S.S.

Crowe

T.M.

Gaines

M.V.

Dynamic incremental CT: effect of volume and concentration of contrast material and patient weight on hepatic enhancement

Radiology 1995; 195:353–357.

15.

Ichikawa

Erturk

S.M.

Araki

Multiphasic contrast-enhanced multidetector-row CT of liver: contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material

Eur J Radiol 2006; 58:165–176.

16.

Kormano

Partanen

Soimakallio

Kivimaki

Dynamic contrast enhancement of the upper abdomen: effect of contrast medium and body weight

Invest Radiol 1983; 18:364–367.

17.

Yamashita

Komohara

Takahashi

Abdominal helical CT: evaluation of optimal doses of intravenous contrast material–a prospective randomized study

Radiology 2000; 216:718–723.

18.

Awai

Kanematsu

Kim

The optimal body size index with which to determine iodine dose for hepatic dynamic CT: a prospective multicenter study

Radiology 2016; 278:773–781.

19.

L.M.

Nelson

R.C.

Delong

D.M.

Determining contrast medium dose and rate on basis of lean body weight: does this strategy improve patient-to-patient uniformity of hepatic enhancement during multi-detector row CT?

Radiology 2007; 243:431–437.

20.

Kidoh

Nakaura

Oda

Contrast enhancement during hepatic computed tomography: effect of total body weight, height, body mass index, blood volume, lean body weight, and body surface area

J Comput Assist Tomogr 2013; 37:159–164.

21.

Kondo

Kanematsu

Goshima

Abdominal multidetector CT in patients with varying body fat percentages: estimation of optimal contrast material dose

Radiology 2008; 249:872–877.

22.

Kondo

Kanematsu

Goshima

Body size indices to determine iodine mass with contrast-enhanced multi-detector computed tomography of the upper abdomen: does body surface area outperform total body weight or lean body weight?

Eur Radiol 2013; 23:1855–1861.

23.

Awai

Hiraishi

Hori

Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight

Radiology 2004; 230:142–150.

24.

Awai

Hori

Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT

Eur Radiol 2003; 13:2155–2160.

25.

Kondo

Kanematsu

Goshima

Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT: comparison of total body weight, lean body weight, and blood volume

Radiology 2010; 254:163–169.

26.

Sultana

Awai

Nakayama

Hypervascular hepatocellular carcinomas: bolus tracking with a 40-detector CT scanner to time arterial phase imaging

Radiology 2007; 243:140–147.

27.

Ichikawa

Okada

Kondo

Recommended iodine dose for multiphasic contrast-enhanced mutidetector-row computed tomography imaging of liver for assessing hypervascular hepatocellular carcinoma: multicenter prospective study in 77 general hospitals in Japan

Acad Radiol 2013; 20:1130–1136.

28.

Yanaga

Awai

Nakaura

Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT

AJR Am J Roentgenol 2008; 190:1003–1009.

29.

Rengo

Bellini

De Cecco

C.N.

The optimal contrast media policy in CT of the liver. Part I: Technical notes

Acta Radiol 2011; 52:467–472.

30.

Noda

Kanematsu

Goshima

Reducing iodine load in hepatic CT for patients with chronic liver disease with a combination of low-tube-voltage and adaptive statistical iterative reconstruction

Eur J Radiol 2015; 84:11–18.

31.

Murakami

Kim

Takamura

Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT

Radiology 2001; 218:763–767.

32.

Yamaguchi

Kidoya

Suzuki

Kimura

Optimizing scan timing of hepatic arterial phase by physiologic pharmacokinetic analysis in bolus-tracking technique by multi-detector row computed tomography

Radiol Phys Technol 2011; 4:43–52.

33.

Davenport

M.S.

Khalatbari

Cohan

R.H.

Dillman

J.R.

Myles

J.D.

Ellis

J.H.

Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate

Radiology 2013; 268:719–728.

34.

Davenport

M.S.

Khalatbari

Dillman

J.R.

Cohan

R.H.

Caoili

E.M.

Ellis

J.H.

Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material

Radiology 2013; 267:94–105.

35.

McDonald

J.S.

McDonald

R.J.

Carter

R.E.

Katzberg

R.W.

Kallmes

D.F.

Williamson

E.E.

Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate

Radiology 2014; 271:65–73.

36.

McDonald

J.S.

McDonald

R.J.

Comin

Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis

Radiology 2013; 267:119–128.

37.

McDonald

R.J.

McDonald

J.S.

Bida

J.P.

Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?

Radiology 2013; 267:106–118.

38.

American College of Radiology. ACR Manual on Contrast Media, Version 10.2. Available at: http://www.acr.org/Quality-Safety/Resources/Contrast-Manual. Accessed August 17, 2016.

39.

Bracco Diagnostics. Isovue-370 full Prescribing Information Sheet. Available at: http://imaging.bracco.com/us-en/products-and-solutions/contrast-media/isovue/prescribing-information. Accessed December 10, 2016.

40.

Schindera

S.T.

Nelson

R.C.

Mukundan

Jr.

Hypervascular liver tumors: low tube voltage, high tube current multi-detector row CT for enhanced detection–phantom study

Radiology 2008; 246:125–132.

41.

Marin

Nelson

R.C.

Samei

Hypervascular liver tumors: low tube voltage, high tube current multidetector CT during late hepatic arterial phase for detection–initial clinical experience

Radiology 2009; 251:771–779.

42.

Nakaura

Awai

Maruyama

Abdominal dynamic CT in patients with renal dysfunction: contrast agent dose reduction with low tube voltage and high tube current-time product settings at 256-detector row CT

Radiology 2011; 261:467–476.

43.

Yanaga

Awai

Nakaura

Hepatocellular carcinoma in patients weighing 70 kg or less: initial trial of compact-bolus dynamic CT with low-dose contrast material at 80 kVp

AJR Am J Roentgenol 2011; 196:1324–1331.

44.

Tanaka

Kozawa

Inoue

Okamoto

Toya

Sato

Should the dose of contrast medium be determined solely on the basis of body weight regardless of the patient's sex?

Jpn J Radiol 2011; 29:330–334.

45.

Svensson

Nouhad

Cederlund

Hepatic contrast medium enhancement at computed tomography and its correlation with various body size measures

Acta Radiol 2012; 53:601–606.